薄膜细胞淋巴瘤中的布鲁顿氨酸激酶抑制剂:目前的选择是什么?
Santino Caserta1, Enrica Antonia Martino1, Ernesto Vigna1
1Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy.
European journal of haematology
|September 13, 2025
概括
覆盖细胞淋巴瘤 (MCL) 治疗正在使用布鲁顿的氨酸激酶 (BTK) 抑制剂发展,为复发患者提供了新的希望. 研究重点是克服耐药性,并通过组合疗法和精准医学改善结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 薄膜细胞淋巴瘤 (MCL) 是一种具有不良预后的侵袭性B细胞非霍奇金淋巴瘤.
- 导致cyclin D1过度表达的t(11;14) 转位是MCL的特征.
- 尽管初始治疗成功,但MCL经常复发,需要新的治疗策略.
研究的目的:
- 审查目前的布鲁顿氨酸激酶 (BTK) 抑制剂在MCL治疗中的情况.
- 讨论包括耐药性机制和与BTK抑制剂相关的毒性在内的挑战.
- 探索新兴的结合策略和精准医学方法来治疗MCL.
主要方法:
- 对MCL中BTK抑制剂的临床试验和临床前研究的文献综述.
- 对抗性机制和瘤微环境相互作用的分析.
- 评估新型治疗组合和基于生物标志物的策略.
主要成果:
- BTK 抑制剂 (易布鲁丁尼布,阿卡拉布鲁丁尼布,皮尔托布鲁丁尼布) 在复发性/耐药性MCL中表现出显著的疗效.
- 耐药性突变 (例如BTK C481S) 和瘤微环境对BTK抑制剂治疗构成挑战.
- 下一代可逆BTK抑制剂在耐药病例中表现出更好的耐受性和活性.
结论:
- 抑制BTK是MCL治疗的基石,特别是在复发性/耐药性疾病中.
- 组合疗法 (例如,使用BCL-2抑制剂,免疫疗法) 对于提高反应耐久性至关重要.
- 使用生物标志物的个性化治疗方法对于优化MCL管理至关重要.
更多相关视频
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
447
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
447
Receptor Tyrosine Kinases
18.0K
Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
18.0K
Tumor Immunotherapy
1.8K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.8K

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
